I agree with Ibraheem Shaikh. Many affordable medicine or medical devices are developed by new firms that are also smaller in terms of financial resources. When every aspect of innovation and translation to a product is a big hurdle, this revised fee may detrimental to such companies.Even though such bills go through several revisions before congress passes it, big companies will certainly have an active role in such activities (lobbying). Furthermore, even if taxpayer’s money is saved, probably the price for new products or devices are going to be much more expensive which can be counter productive.